JP2021520210A - 抗ケモカイン様受容体１抗体及びその治療応用 - Google Patents

抗ケモカイン様受容体１抗体及びその治療応用 Download PDF

Info

Publication number
JP2021520210A
JP2021520210A JP2020554298A JP2020554298A JP2021520210A JP 2021520210 A JP2021520210 A JP 2021520210A JP 2020554298 A JP2020554298 A JP 2020554298A JP 2020554298 A JP2020554298 A JP 2020554298A JP 2021520210 A JP2021520210 A JP 2021520210A
Authority
JP
Japan
Prior art keywords
seq
cmklr1
antibody
amino acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020554298A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019193029A5 (enExample
Inventor
ニコラ・ポワリエ
カロリーヌ・マリー
ベルナール・ヴァンオヴ
ヴァネッサ・ゴーティエ
シャルレーヌ・トリレオ
マルク・デュブルドー
Original Assignee
オーエスイー・イミュノセラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーエスイー・イミュノセラピューティクス filed Critical オーエスイー・イミュノセラピューティクス
Publication of JP2021520210A publication Critical patent/JP2021520210A/ja
Publication of JPWO2019193029A5 publication Critical patent/JPWO2019193029A5/ja
Priority to JP2024081730A priority Critical patent/JP2024105648A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020554298A 2018-04-03 2019-04-03 抗ケモカイン様受容体１抗体及びその治療応用 Pending JP2021520210A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024081730A JP2024105648A (ja) 2018-04-03 2024-05-20 抗ケモカイン様受容体１抗体及びその治療応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305395 2018-04-03
EP18305395.8 2018-04-03
PCT/EP2019/058358 WO2019193029A1 (en) 2018-04-03 2019-04-03 Anti-chemokin like receptor 1 antibodies and their therapeutic applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024081730A Division JP2024105648A (ja) 2018-04-03 2024-05-20 抗ケモカイン様受容体１抗体及びその治療応用

Publications (2)

Publication Number Publication Date
JP2021520210A true JP2021520210A (ja) 2021-08-19
JPWO2019193029A5 JPWO2019193029A5 (enExample) 2022-05-10

Family

ID=62046804

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020554298A Pending JP2021520210A (ja) 2018-04-03 2019-04-03 抗ケモカイン様受容体１抗体及びその治療応用
JP2024081730A Revoked JP2024105648A (ja) 2018-04-03 2024-05-20 抗ケモカイン様受容体１抗体及びその治療応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024081730A Revoked JP2024105648A (ja) 2018-04-03 2024-05-20 抗ケモカイン様受容体１抗体及びその治療応用

Country Status (11)

Country Link
US (2) US20210147558A1 (enExample)
EP (2) EP4656247A2 (enExample)
JP (2) JP2021520210A (enExample)
KR (2) KR102802041B1 (enExample)
CN (2) CN112218894A (enExample)
AU (1) AU2019247068A1 (enExample)
BR (1) BR112020020118A2 (enExample)
CA (1) CA3102607A1 (enExample)
IL (2) IL277701A (enExample)
MA (1) MA52174A (enExample)
WO (1) WO2019193029A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730705B2 (en) * 2019-05-02 2023-08-22 The Board Of Trustees Of The Leland Stanford Junior University Small molecule CMKLR1 antagonists in inflammatory disease
EP3804754A1 (en) * 2019-10-09 2021-04-14 OSE Immunotherapeutics Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications
US20240084019A1 (en) * 2019-10-09 2024-03-14 Ose Immunotherapeutics Anti-Chemokin Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications
EP4279142A4 (en) 2021-01-15 2024-12-04 Reel Tech Co., Ltd. PORTABLE EMERGENCY ESCAPE DEVICE
US11986512B2 (en) 2021-10-26 2024-05-21 Thetis Phamaceuticals LLC Compositions and methods for cancer therapy
WO2024028508A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis
WO2024028509A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Treatment of an inflammation-associated disease in a patient expressing high chemerin level

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
US20090280113A1 (en) * 2008-05-10 2009-11-12 Kareem Graham Target for regulating multiple sclerosis
WO2013117518A2 (en) * 2012-02-06 2013-08-15 Asml Netherlands B.V. Lithographic apparatus comprising a support for holding an object, and a support for use therein
US20150025153A1 (en) * 2012-01-20 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Small Molecule CMKLR1 Antagonists in Demyelinating Disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
CN102816209A (zh) * 2012-07-09 2012-12-12 深圳先进技术研究院 一种趋化素衍生肽及其表达基因和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
US20090280113A1 (en) * 2008-05-10 2009-11-12 Kareem Graham Target for regulating multiple sclerosis
US20150025153A1 (en) * 2012-01-20 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Small Molecule CMKLR1 Antagonists in Demyelinating Disease
WO2013117518A2 (en) * 2012-02-06 2013-08-15 Asml Netherlands B.V. Lithographic apparatus comprising a support for holding an object, and a support for use therein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XAVIER PEYRASSOL ET AL.: ""Development by GeneticImmunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists o", THE JOURNAL OF IMMUNOLOGY, vol. 196, no. 6, JPN6023009817, 15 March 2016 (2016-03-15), pages 2893 - 2901, ISSN: 0005369890 *

Also Published As

Publication number Publication date
US20210147558A1 (en) 2021-05-20
JP2024105648A (ja) 2024-08-06
IL277701A (en) 2020-11-30
CN120484119A (zh) 2025-08-15
WO2019193029A1 (en) 2019-10-10
AU2019247068A1 (en) 2020-10-22
IL321209A (en) 2025-07-01
MA52174A (fr) 2021-02-17
KR102802041B1 (ko) 2025-04-30
KR20210006359A (ko) 2021-01-18
BR112020020118A2 (pt) 2021-02-23
KR20250065423A (ko) 2025-05-12
US20240400698A1 (en) 2024-12-05
EP3774899A1 (en) 2021-02-17
CN112218894A (zh) 2021-01-12
EP4656247A2 (en) 2025-12-03
CA3102607A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
KR102714165B1 (ko) 인간 cd137에 결합하는 작동자 항체 및 이의 용도
JP2024105648A (ja) 抗ケモカイン様受容体１抗体及びその治療応用
US20250154244A1 (en) Anti-il-27 antibodies and uses thereof
US12358978B2 (en) Anti-IL-27 antibodies and uses thereof
JP7701915B2 (ja) 抗ケモカイン様受容体１ヒト化抗体及びその治療適用
JP2022502417A (ja) 抗ｏｘ４０抗体、その抗原結合フラグメント、および医薬用途
US20220389089A1 (en) Anti-il-27 antibodies and uses thereof
WO2024028508A2 (en) Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis
EA049261B1 (ru) Гуманизированные антитела против хемокин-подобного рецептора 1 и их терапевтические применения
WO2024028509A2 (en) Treatment of an inflammation-associated disease in a patient expressing high chemerin level
OA21239A (en) Anti-chemokin like receptor 1 humanized antibodies and their therapeutic applications.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240716

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240808

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240808